The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey. (Q51850263)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20517698%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

title

The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20517698%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

0 references

1 reference

A. ELIF ANIL YAGCIOGLU

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20517698%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

M K Yazici

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20517698%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

A Ertuğrul

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20517698%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

N Eni

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20517698%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

S Karahan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20517698%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

E Karaağaoğlu

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20517698%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

S L Tokgözoğlu

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20517698%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

publication date

3 June 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20517698%20AND%20SRC:MED&resulttype=core&format=json

European Archives of Psychiatry and Clinical Neuroscience

4 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20517698%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

volume

261

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20517698%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20517698%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

page(s)

69-78

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20517698%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00406-010-0118-x

4 February 2020

exact match

0 references

cites work

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

Follow-up report on the diagnosis of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

Prevalence of Metabolic Syndrome in Hispanic and Non-Hispanic Patients With Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

The prevalence of the metabolic syndrome in patients with schizoaffective disorder--bipolar subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

Prevalence of the metabolic syndrome in veterans with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

The prevalence of metabolic syndrome among psychiatric inpatients in Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

Body mass index as a screening test for metabolic syndrome in schizophrenia and schizoaffective disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

Prevalence of metabolic syndrome among inpatients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

Prevalence and predictors of metabolic syndrome among patients attending an outpatient clozapine clinic in Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

Prediction of Coronary Heart Disease Using Risk Factor Categories

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiolog

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

Differential metabolic effects of antipsychotic treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

Which comes first: atypical antipsychotic treatment or cardiometabolic risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

The prevalence of the metabolic syndrome in psychiatric inpatients with primary psychotic and mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-010-0118-X

Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: a corollary from the CLAMORS study.

21 January 2018

1 reference

12 December 2020

Metabolic syndrome in patients with schizophrenia.

1 reference

12 December 2020

A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study

1 reference

12 December 2020

Metabolic syndrome in people with schizophrenia: a review.

1 reference

12 December 2020

Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review

1 reference

12 December 2020

Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome

1 reference

12 December 2020

Prevalence of the metabolic syndrome among patients receiving clozapine

1 reference

12 December 2020

The prevalence of metabolic syndrome and related factors in patients with schizophrenia

1 reference

12 December 2020

Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study

1 reference

12 December 2020

The prevalence and predictive value of individual criteria for metabolic syndrome in schizophrenia: a Northern Finland 1966 Birth Cohort Study

1 reference

12 December 2020

Prevalence of the metabolic syndrome among Turkish adults

1 reference

12 December 2020

Prevalence of the metabolic syndrome among schizophrenic patients hospitalized in the Canary Islands.

1 reference

12 December 2020

A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study

1 reference

12 December 2020

Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs.

1 reference

12 December 2020

10.1007/S00406-010-0118-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20517698%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference